Abstract
Identification of key phenotypic regions such as necrosis, contrast enhancement, and edema on magnetic resonance imaging (MRI) is important for understanding disease evolution and treatment response in patients with glioma. Manual delineation is time intensive and not feasible for a clinical workflow. Automating phenotypic region segmentation overcomes many issues with manual segmentation, however, current glioma segmentation datasets focus on pre-treatment, diagnostic scans, where treatment effects and surgical cavities are not present. Thus, existing automatic segmentation models are not applicable to post-treatment imaging that is used for longitudinal evaluation of care. Here, we present a comparison of three-dimensional convolutional neural networks (nnU-Net architecture) trained on large temporally defined pre-treatment, post-treatment, and mixed cohorts. We used a total of 1563 imaging timepoints from 854 patients curated from 13 different institutions as well as diverse public data sets to understand the capabilities and limitations of automatic segmentation on glioma images with different phenotypic and treatment appearance. We assessed the performance of models using Dice coefficients on test cases from each group comparing predictions with manual segmentations generated by trained technicians. We demonstrate that training a combined model can be as effective as models trained on just one temporal group. The results highlight the importance of a diverse training set, that includes images from the course of disease and with effects from treatment, in the creation of a model that can accurately segment glioma MRIs at multiple treatment time points.
Competing Interest Statement
KRS is a co-founders of Precision Oncology Insights Inc; the remaining authors have no relevant conflicts of interest to disclose.
Funding Statement
The authors would like to thank the numerous members of the image analysis team that have given their time, attention, and talent over the years to generate tumor segmentations. We are truly grateful to our funding sources: Mayo Clinic Marley Endowment Funds, NIH grants U01CA220378, U01CA250481, R01NS060752, R01CA164371, U54CA143970, U54CA193489, U54CA210180, the James S. McDonnell Foundation, and the Ben and Catherine Ivy Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Mayo Clinic (#17-009688) gave ethical approval of data collection for the repository that holds data used in this research. Prior to collection of retrospective data, informed consent was waived for those participants by the IRB of Mayo Clinic (#15-002337). Written informed consent was obtained for all prospectively enrolled participants (#17-009682).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
ranjbar.sara{at}mayo.edu
Data Availability
Due to the proprietary nature of patient data and patient information, we are not at liberty to freely share data with readers. However, data may be available for sharing upon the reasonable request of qualified parties as long as patient privacy and intellectual property interests of our institution are not compromised.
